# EPLERAF-Study: Eplerenone in the Prevention of Atrial Fibrillation Recurrences After Cardioversion

> **NCT00647192** · PHASE2 · TERMINATED · sponsor: **University Hospital, Saarland** · enrollment: 38 (actual)

## Conditions studied

- Atrial Fibrillation

## Interventions

- **DRUG:** Eplerenone
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00647192
- **Lead sponsor:** University Hospital, Saarland
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-03
- **Primary completion:** 2012-02
- **Final completion:** 2012-02
- **Target enrollment:** 38 (ACTUAL)
- **Why stopped:** Inclusion rate too low. Recruitment of further study centers too costly.
- **Last updated:** 2012-02-10

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00647192

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00647192, "EPLERAF-Study: Eplerenone in the Prevention of Atrial Fibrillation Recurrences After Cardioversion". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00647192. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*